Aldeyra Therapeutics (NASDAQ:ALDX): Cantor Fitzgerald Reconfirms Buy Rating Today, Has a Target of $23.0000/Share

May 17, 2018 - By Marguerite Chambers

Investors sentiment decreased to 1.62 in 2017 Q4. Its down 1.51, from 3.13 in 2017Q3. It turned negative, as 5 investors sold Aldeyra Therapeutics, Inc. shares while 8 reduced holdings. 9 funds opened positions while 12 raised stakes. 9.98 million shares or 45.35% less from 18.26 million shares in 2017Q3 were reported.

Renaissance Technology Ltd Limited Liability Company reported 0% of its portfolio in Aldeyra Therapeutics, Inc. (NASDAQ:ALDX). Hikari Power Ltd stated it has 107,858 shares. Vanguard Group Inc Inc Inc reported 698,534 shares. Prelude Capital holds 0% or 1,353 shares. Dimensional Fund Advisors Ltd Partnership has 50,923 shares for 0% of their portfolio. Moreover, Private Ocean Ltd has 0% invested in Aldeyra Therapeutics, Inc. (NASDAQ:ALDX). Northern Trust stated it has 35,861 shares or 0% of all its holdings. Hightower Limited has invested 0% of its portfolio in Aldeyra Therapeutics, Inc. (NASDAQ:ALDX). Moreover, Macquarie Group Inc has 0% invested in Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) for 1,400 shares. Ardsley Advisory Ptnrs invested 0.04% in Aldeyra Therapeutics, Inc. (NASDAQ:ALDX). Knoll Cap Mngmt L P invested in 124,096 shares or 0.74% of the stock. Peddock Cap Advisors Ltd Liability Co holds 0% or 752 shares in its portfolio. Blackrock Inc has invested 0% in Aldeyra Therapeutics, Inc. (NASDAQ:ALDX). Acadian Asset Limited Liability Company holds 5,534 shares. Massachusetts-based Adage Capital Prtnrs Grp Incorporated Ltd Liability Corp has invested 0.01% in Aldeyra Therapeutics, Inc. (NASDAQ:ALDX).

Aldeyra Therapeutics (NASDAQ:ALDX) Rating Reaffirmed

New York: In a research note revealed to investors and clients on 15 May, Cantor Fitzgerald reiterated their Buy rating on Aldeyra Therapeutics (NASDAQ:ALDX) shares. They now have a $23.0000 target price per share on the firm. Cantor Fitzgerald’s target gives a potential upside of 158.43 % from the company’s last stock price.

Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) Ratings Coverage

Among 2 analysts covering Aldeyra Therapeutics (NASDAQ:ALDX), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Aldeyra Therapeutics has $2300 highest and $13 lowest target. $18’s average target is 102.25% above currents $8.9 stock price. Aldeyra Therapeutics had 2 analyst reports since January 26, 2018 according to SRatingsIntel. The stock has “Buy” rating by Cantor Fitzgerald on Thursday, March 29.

The stock increased 5.33% or $0.45 during the last trading session, reaching $8.9. About 117,719 shares traded or 25.81% up from the average. Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) has risen 55.45% since May 17, 2017 and is uptrending. It has outperformed by 43.90% the S&P500.

Aldeyra Therapeutics, Inc., a biotechnology company, focuses on the development of products for inflammation, inborn errors of metabolism, and other diseases in the United States and internationally. The company has market cap of $175.02 million. It is developing ADX-102, a small molecule designed to trap and allow for the degradation of aldehydes, as well as ADX-103 and ADX-104 novel candidates for the treatment of noninfectious anterior uveitis, allergic conjunctivitis, dry eye syndrome, sjgren-larsson syndrome, and succinic semi-aldehyde dehydrogenase deficiency. It currently has negative earnings. The firm was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014.

More notable recent Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) news were published by: Benzinga.com which released: “22 Stocks Moving In Friday’s Pre-Market Session” on May 11, 2018, also Seekingalpha.com with their article: “Aldeyra Therapeutics (ALDX) CEO Dr. Todd Brady on Q1 2018 Results – Earnings Call Transcript” published on May 15, 2018, Seekingalpha.com published: “2 Small Biotechs To Consider” on April 27, 2018. More interesting news about Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) were released by: Benzinga.com and their article: “Earnings Scheduled For May 15, 2018” published on May 15, 2018 as well as Benzinga.com‘s news article titled: “Benzinga’s Daily Biotech Pulse: Aytu Rallies On Earnings, Evolus Awaits FDA Verdict, BofA Conference Underway” with publication date: May 15, 2018.

Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.